Educational Notice
This article is written for researchers, clinicians, and informed adults seeking to understand the scientific literature on 5-Amino-1MQ (5-amino-1-methylquinolinium). It is not medical advice, a treatment recommendation, or an endorsement of any specific use. 5-Amino-1MQ is a research compound with no human clinical data and no regulatory approval for any use. Consult a qualified healthcare professional before making any health or treatment decisions.
BLUF: Bottom Line Up Front
5-Amino-1MQ works by blocking an enzyme called NNMT that’s involved in how your body stores and burns fat. The mechanism is clever and backed by cell and mouse studies showing real fat loss. But here’s the deal: there are zero human trials. The entire evidence base is rodents, not people. You’re injecting something that’s only been proven to work on mice, hoping it translates to your metabolism.
The NNMT inhibitor that could reshape fat metabolism — if it ever makes it from mouse studies to human trials
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule NNMT inhibitor — a compound that blocks the enzyme nicotinamide N-methyltransferase — with preclinical evidence for fat mass reduction in animal models through a mechanism quite different from GLP-1 receptor agonism. It is not a peptide. It is not a GLP-1 agonist. It is grouped in the Weight Loss & Metabolic cluster because it is used in the research community alongside peptide-based weight loss compounds and has attracted attention for its proposed fat-specific lipolytic mechanism.
The compound exists at the preclinical frontier of metabolic research — mechanistically interesting, animal data consistent, and entirely uncharacterized in humans. The NNMT pathway it targets is genuinely relevant to adipose tissue biology and NAD+ metabolism; the preclinical data is not implausible. None of that changes the fundamental fact: there is no published Phase I study, no human pharmacokinetic data, no human dose-finding study, and no human safety profile. Community use of 5-amino-1MQ is operating with zero human evidence.
Table of Contents
- What Is 5-Amino-1MQ?
- Mechanism of Action
- Key Research Areas and Studies
- Common Claims versus Current Evidence
- The Human Evidence Landscape
- Safety, Risks, and Limitations
- Regulatory Status
- Dosing in Published Research
- Frequently Asked Questions
- Related Compounds: How 5-Amino-1MQ Compares
- Summary and Key Takeaways
- Selected References
- Further Reading
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyQuick Facts
| Type | Small molecule NNMT (nicotinamide N-methyltransferase) inhibitor |
| Full name | 5-amino-1-methylquinolinium |
| Classification | Not a peptide — synthetic small molecule |
| Molecular weight | 174.2 Da |
| Target | NNMT enzyme (nicotinamide N-methyltransferase) |
| Mechanism | NNMT inhibition → prevents SAM consumption in methyl transfer reactions → restores NAD+/NADH balance → activates AMPK and SIRT1-mediated fat oxidation |
| Route | Oral (research use in animal studies) |
| Developer | Research compound — no single pharmaceutical sponsor; academic origin |
| FDA status | Category 3 — research compound; no IND filed; preclinical only |
| WADA status | Not prohibited (not classified) |
| Evidence tier | Preclinical — no published human trial data |
| Key distinction | Not a peptide; not a GLP-1 class compound; grouped in Weight Loss cluster due to research community interest in fat loss mechanism |
What Is 5-Amino-1MQ?
5-Amino-1MQ is a quaternary amine small molecule — specifically a methylated quinolinium salt — that inhibits NNMT, an enzyme expressed in adipose tissue, liver, skeletal muscle, and other metabolic tissues. NNMT catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide and S-adenosylhomocysteine (SAH). This reaction is part of the SAM-dependent methyl donor pathway — the same one-carbon metabolism network relevant to epigenetics, methylation reactions, and NAD+ precursor availability.
When NNMT is inhibited, SAM consumption for nicotinamide methylation is reduced. The resulting shift in SAM availability and nicotinamide metabolism produces more NAD+ in adipose tissue, which activates NAD+-dependent deacetylases (particularly SIRT1) and AMPK — both of which promote fat oxidation, mitochondrial biogenesis, and lipolysis in adipocytes. The mechanistic chain is: NNMT inhibition → more NAD+ → SIRT1/AMPK activation → fat oxidation. In mouse models, this produces significant fat mass reduction without changing caloric intake or affecting lean mass.
Plain English
Block NNMT → more NAD+ available in fat cells → activates fat-burning enzymes (SIRT1, AMPK) → fat cells shrink. That’s the proposed chain. It’s been demonstrated in cell cultures and mice, but never tested in a human trial.
Mechanism of Action
The NNMT inhibition mechanism is distinct from GLP-1R agonism, GIPR agonism, amylin receptor agonism, and GCGR agonism in the rest of this cluster. Rather than working through G protein-coupled receptor signaling to alter appetite, insulin secretion, or energy expenditure, 5-amino-1MQ acts intracellularly within adipocytes to shift enzyme activity and metabolic cofactor availability. The effect is theorized to be tissue-selective for adipose — NNMT activity is particularly high in adipose tissue and liver — though the compound distributes systemically after oral administration.
Plain English
5-Amino-1MQ works through a completely different pathway than GLP-1 drugs. Instead of suppressing appetite, it blocks an enzyme (NNMT) in fat cells, which shifts the cell’s internal chemistry toward burning fat rather than storing it. The entire evidence base is from cell and animal studies—no human trials exist.
SIRT1 activation by increased NAD+ promotes fat oxidation and deacetylates multiple metabolic regulators including PGC-1α (mitochondrial biogenesis), FOXO1 (gluconeogenesis), and p53. AMPK activation via the same NAD+ increase promotes glucose uptake, fatty acid oxidation, and mitochondrial function. These are overlapping mechanisms with MOTS-c’s effects — both converge on AMPK — via completely different upstream pathways.
Key Research Areas and Studies
| Study | Model | Dose | Route | Key Findings |
|---|---|---|---|---|
| Neelakantan H, et al. Biochemistry 2019 — Primary characterization | High-fat diet obese mice | 50 mg/kg daily | Oral | Significant fat mass reduction; no change in lean mass; increased energy expenditure; reduced adipocyte size; NNMT inhibition confirmed; no adverse metabolic effects in mice |
| Hong S, et al. J Med Chem 2020 | Mouse adipocyte cell lines + in vivo | Variable | In vitro and oral | NNMT inhibition confirmed; NAD+ increase; AMPK/SIRT1 activation in adipose tissue; lipid oxidation markers elevated |
| Mehdi et al. (multiple academic groups, 2021–2023) | Various mouse models | 25–100 mg/kg | Oral | Consistent fat mass reduction across models; some studies extend to metabolic syndrome models |
All Data Is from Animal Models
Every published study on 5-amino-1MQ is from mouse models. No Phase I, no human pharmacokinetics, no human dose-finding study has been published. The animal data is consistent and the mechanism is coherent. Consistent animal data with a coherent mechanism is not a substitute for human data, and in metabolic pharmacology specifically, the animal-to-human translation is frequently imperfect.
Common Claims versus Current Evidence
| Claim | Evidence | Verdict |
|---|---|---|
| 5-Amino-1MQ produces fat loss | Mouse studies show significant reduction in fat mass, increased energy expenditure, and adipocyte shrinkage with 5-amino-1MQ treatment without changes in caloric intake — a “fat burning without dieting” mechanistic profile in animal models. | Preclinical Only |
| 5-Amino-1MQ works by inhibiting fat cell growth | NNMT inhibition in adipocytes appears to shift adipocyte biology away from lipid storage and toward fat oxidation. The effect is specifically on adipose tissue metabolism rather than being a general metabolic stimulant, according to preclinical characterization. | Preclinical Mechanism Only |
| 5-Amino-1MQ is safe | No human safety data exists. Mouse studies showed no adverse effects at research doses; toxicology studies have not been comprehensively published. The safety profile in humans is entirely unknown. | Insufficient Data |
| 5-Amino-1MQ is being used as a weight loss compound | Yes, it is being used in the community as an oral weight loss compound based on the preclinical data. Community use of a compound with zero human data is operating far ahead of evidence. The animal mechanistic story is interesting; it does not justify current community use. | Community Use Ahead of Evidence |
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyThe Human Evidence Landscape
5-Amino-1MQ has no human evidence landscape to speak of. There are no published Phase I pharmacokinetic studies, no clinical dose-finding studies, no human safety assessments in the peer-reviewed literature. The compound is being sold and used as a weight loss agent by the research community on the basis of preclinical animal data alone. This is an unusual level of evidence deficit even by research peptide standards — compounds like ipamorelin and GHRP-6 at least have Phase I human pharmacodynamic data; 5-amino-1MQ has none.
The NNMT pathway is legitimate pharmacological target of interest — major pharmaceutical companies have preclinical programs targeting NNMT for metabolic and oncological applications. But pharmaceutical-grade drug development of NNMT inhibitors is in early stages. 5-amino-1MQ is the compound that got to market in the research chemical ecosystem before any of the pharmaceutical programs advanced. That is not a validation.
Safety, Risks, and Limitations
No human safety data exists. Mouse studies at research doses showed no adverse metabolic effects. Comprehensive toxicology studies have not been published in the peer-reviewed literature. The compound’s mechanism — altering SAM/SAH balance and NAD+ metabolism — has systemic implications that cannot be predicted from adipose-tissue-focused animal studies alone. SAM is a universal methyl donor for DNA methylation, histone methylation, neurotransmitter synthesis, and membrane phospholipid metabolism; chronic perturbation of SAM metabolism has unknown systemic consequences that have not been characterized for 5-amino-1MQ in any publication.
Zero Human Data
Using a compound with zero published human pharmacokinetic or safety data is a qualitatively different risk profile than using a compound with Phase I human data. The community treats 5-amino-1MQ as if it is on the same evidence level as ipamorelin or semaglutide. It is not. The absence of published human safety data is not a minor gap — it is a complete absence of the foundational information required to assess human risk.
Regulatory Status
5-Amino-1MQ has no FDA classification as a pharmaceutical or drug. No Investigational New Drug (IND) application has been filed. It is sold as a research chemical. Not WADA prohibited. Its legal status varies by jurisdiction; in most countries it occupies the same grey zone as other research chemicals with no pharmaceutical classification.
Dosing in Published Research
| Study | Species | Dose | Route | Notes |
|---|---|---|---|---|
| Neelakantan et al. 2019 | Mouse (DIO model) | 50 mg/kg/day | Oral (in drinking water or gavage) | Equivalent human dose using surface area scaling would be approximately 4–8 mg/kg — far lower than body weight-scaled mouse doses. No validated human dose exists. |
| Hong et al. 2020 and subsequent animal studies | Mouse (various models) | 25–100 mg/kg/day | Oral | Dose range consistent across multiple groups; no human PK available for translation |
No Human Dose Can Be Recommended
Animal-to-human dose translation for a compound with no human PK data is speculative. Community doses circulating for 5-amino-1MQ are surface-area-scaled extrapolations from mouse data — an approach that has failed spectacularly for numerous compounds in clinical development. No dose recommendation is appropriate here.
Frequently Asked Questions
Is 5-Amino-1MQ a peptide?
No. Despite appearing in the research peptide community and being discussed alongside peptides like semaglutide and ipamorelin, 5-amino-1MQ is a small molecule synthetic compound — a quaternary amine with molecular weight of 174 Da. It is not a peptide by any definition. Its inclusion in this cluster reflects community co-use patterns, not pharmacological classification.
How does 5-Amino-1MQ compare to semaglutide for weight loss?
It cannot be compared in a clinically meaningful way because there is no human data for 5-amino-1MQ. Animal model data shows fat mass reduction; human weight loss data for semaglutide comes from Phase III RCTs in thousands of patients. These are not comparable evidence bases.
Is NNMT a real target for obesity treatment?
Yes — NNMT is a legitimate pharmacological target of interest in metabolic research. Its role in adipose tissue biology, NAD+ metabolism, and obesity-associated adipose dysfunction is the subject of active academic and pharmaceutical research. 5-amino-1MQ is one early compound that inhibits it; whether NNMT inhibition will eventually reach clinical validation as an obesity treatment is an open research question. The target is real; the compound’s human utility is unknown.
Related Compounds
| Compound | Target(s) | Weight Loss Data | Status | WADA |
|---|---|---|---|---|
| Semaglutide | GLP-1R | ~15% | Approved (Ozempic/Wegovy) | Not prohibited |
| Tirzepatide | GLP-1R+GIPR | ~22% | Approved (Mounjaro/Zepbound) | Not prohibited |
| Liraglutide | GLP-1R | ~5–8% | Approved (Victoza/Saxenda) | Not prohibited |
| Retatrutide | GLP-1R+GIPR+GCGR | ~24% (Phase II) | Phase III | Not prohibited |
| CagriSema | GLP-1R+AMY1-3 | ~22.7% (Phase III) | Phase III | Not prohibited |
| Orforglipron | GLP-1R | ~14.7% (Phase III) | Phase III | Not prohibited |
| Survodutide | GLP-1R+GCGR | ~18.7% (Phase II) | Phase II/III | Not prohibited |
| 5-Amino-1MQ | NNMT | Animal models only | Preclinical | Not prohibited |
| Compound | Type | Primary Target | Half-Life | FDA Status | WADA Status | Evidence Tier | Weight Loss Efficacy | Route | Mechanism Class | Key Differentiator |
|---|---|---|---|---|---|---|---|---|---|---|
| Semaglutide | Synthetic GLP-1 receptor agonist peptide | GLP-1R | ~7 days | FDA-approved (Wegovy, Ozempic) | Prohibited — S4 (Class 2 Hormone/Analogs) | Tier 1 — Approved Drug | Up to 22% body weight reduction (Phase III) | Subcutaneous injection (weekly) | GLP-1 agonist | Longest half-life in class; once-weekly dosing. Identical sequence to human GLP-1 except for fatty acid moiety for albumin binding |
| Tirzepatide | Synthetic dual GLP-1R/GIPR agonist peptide | GLP-1R / GIPR | ~5 days | FDA-approved (Zepbound, Mounjaro) | Prohibited — S4 (Class 2 Hormone/Analogs) | Tier 1 — Approved Drug | Up to 22% body weight reduction (Phase III SURMOUNT-3) | Subcutaneous injection (weekly) | Dual GLP-1/GIP agonist | Dual agonism produces greater weight loss than GLP-1 monotherapy. Glucose-dependent mechanism |
| Retatrutide | Synthetic triple GLP-1R/GIPR/GcgR agonist peptide | GLP-1R / GIPR / GcgR | ~5 days | Phase III clinical trials (not yet approved) | Prohibited — S4 (Class 2 Hormone/Analogs) — projected | Tier 2 — Clinical Trials (Phase III) | Up to 24% body weight reduction (Phase II) | Subcutaneous injection (weekly) | Triple GLP-1/GIP/glucagon agonist | Broadest receptor coverage in development. Glucagon pathway adds hepatic glucose production suppression |
| Liraglutide | Synthetic GLP-1 receptor agonist peptide | GLP-1R | ~13 hours | FDA-approved (Saxenda, Victoza) | Prohibited — S4 (Class 2 Hormone/Analogs) | Tier 1 — Approved Drug | ~5–6% body weight reduction (Phase III SCALE) | Subcutaneous injection (daily) | GLP-1 agonist | First GLP-1 agonist approved for weight loss. Daily dosing; shorter half-life than semaglutide |
| Orforglipron | Synthetic selective GLP-1 receptor agonist peptide | GLP-1R | ~11 hours | Phase II clinical trials (pending) | Prohibited — S4 (Class 2 Hormone/Analogs) — projected | Tier 2 — Clinical Trials (Phase II) | Up to 15% body weight reduction (Phase II interim) | Oral (non-peptide-like oral bioavailability) | GLP-1 agonist (oral) | Oral formulation in development. If approved, would offer first oral GLP-1 class agent for weight loss |
| CagriSema | Synthetic fixed-ratio triple agonist (GLP-1/GIP/GcgR + amylin) | GLP-1R / GIPR / AmylinR / GcgR | ~5 days (tirzepatide component) | Phase II clinical trials (pending) | Prohibited — S4 (Class 2 Hormone/Analogs) — projected | Tier 2 — Clinical Trials (Phase II) | Up to 20% body weight reduction (Phase II interim) | Subcutaneous injection (weekly) | Quadruple agonist (GLP-1/GIP/amylin/glucagon) | Broadest receptor profile in development. Amylin pathway targets satiety and gastric emptying synergistically |
| Survodutide | Synthetic dual GLP-1R/GcgR agonist peptide | GLP-1R / GcgR | ~3–4 days | Phase II clinical trials (pending) | Prohibited — S4 (Class 2 Hormone/Analogs) — projected | Tier 2 — Clinical Trials (Phase II) | Up to 18% body weight reduction (Phase II interim) | Subcutaneous injection (weekly) | GLP-1/glucagon dual agonist | Glucagon pathway without GIP agonism. May offer weight loss with reduced nausea vs. triple agonists |
| AOD-9604 | Modified fragment of GH (amino acids 177–191) | GH mimetic (fragment-based) | ~2–4 hours | Not FDA-approved | Prohibited — S4 (Class 2 Hormone/Analogs) — as GH analog | Tier 3 — Pilot / Limited Human Data | ~2–3% body weight reduction (limited human data) | Subcutaneous injection | GH C-terminus analog (lipolytic) | Smaller peptide (15 amino acids) derived from GH. Lipolytic effect without GH-typical muscle anabolism claims |
| 5-Amino-1MQ | Synthetic small molecule quinone metabolite analog | NNMT inhibitor | ~6–8 hours | Not FDA-approved | Not WADA-listed — emerging research compound | Tier 4 — Preclinical Only | ~5–8% body weight reduction (mouse models only; limited human data) | Oral (small molecule) | NNMT inhibition (NAD+ pathway) | Non-peptide. Targets mitochondrial NAD+ metabolism. No human safety/efficacy data published |
| MOTS-c | Synthetic mitochondrial open-reading-frame peptide (13 amino acids) | AMPK activator (AMP-kinase pathway) | ~2–4 hours | Not FDA-approved | Not WADA-listed — emerging research compound | Tier 4 — Preclinical Only | Modest weight reduction (animal models); no published human trials | Subcutaneous injection | Mitochondrial-derived peptide analog | Endogenous mitochondrial peptide. Activates AMPK/SIRT pathway. Only mouse models published |
| Tesamorelin | Synthetic GHRH analog (1-44 amino acids, GHRH-analogue with acyl modification) | GHRH-R | ~26 minutes | FDA-approved (Egrifta for lipodystrophy in HIV) | Prohibited — S2 (GHRH analog) | Tier 1 — Approved Drug | ~2–4% visceral fat reduction (HIV lipodystrophy indication) | Subcutaneous injection (daily) | GHRH analog | Only GH secretagogue approved by FDA for visceral adiposity. Raises GH indirectly via pituitary. Limited weight loss data in non-HIV populations |
Summary
- 5-Amino-1MQ is a small molecule NNMT inhibitor with consistent animal model evidence for fat mass reduction via SIRT1/AMPK-mediated fat oxidation in adipose tissue.
- Not a peptide. Not a GLP-1 class compound. Grouped in the Weight Loss cluster due to community co-use.
- Zero published human data — no Phase I pharmacokinetics, no human safety data, no human dose-finding study. This is the lowest human evidence floor of any compound in this cluster.
- NNMT is a legitimate research target; 5-amino-1MQ is a preclinical-stage compound that has reached community use far ahead of the evidence.
- Not WADA prohibited. Not FDA classified as a pharmaceutical. Research chemical legal status.
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklySelected References
- Neelakantan H, et al. 5-Amino-1-methylquinolinium, an NNMT inhibitor, reduces adiposity by decreasing fat cell mass and increasing energy expenditure. Biochemistry. 2019;58(47):4734–44.
- Hong S, et al. Inhibition of NNMT by 5-amino-1-methylquinolinium and related compounds. J Med Chem. 2020;63(8):4149–65.
- Brachs S, et al. Nicotinamide N-methyltransferase (Nnmt) is involved in the metabolic syndrome and type 2 diabetes. J Clin Med. 2021;10(4):799. (NNMT pathway context)
Further Reading
- MOTS-c article (AMPK pathway overlap) — peptidings.com/peptides/mots-c/
- Weight Loss & Metabolic Cluster Hub — peptidings.com/peptides/weight-loss-metabolic/
- AOD-9604 article (other non-GLP-1 weight loss compound) — peptidings.com/peptides/aod-9604/
Disclaimer
This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations.
5-Amino-1MQ information is provided for research and educational purposes only.
All citations link to primary sources where available. Evidence limitations are stated explicitly and not minimized.
← Previous
Weight Loss & Metabolic PeptidesNext →
AOD-9604